2 resultados para New Thought

em AMS Tesi di Dottorato - Alm@DL - Università di Bologna


Relevância:

30.00% 30.00%

Publicador:

Resumo:

Diffuse radio emission in galaxy clusters has been observed with different size and properties. Giant radio halos (RH), Mpc-size sources found in merging clusters, and mini halos (MH), 0.1-0.5 Mpc size sources located in relaxed cool-core clusters, are thought to be distinct classes of objects with different formation mechanisms. However, recent observations have revealed the unexpected presence of diffuse emission on Mpc-scales in relaxed clusters that host a central MH and show no signs of major mergers. The study of these sources is still at the beginning and it is not yet clear what could be the origin of their unusual emission. The main goal of this thesis is to test the occurrence of these peculiar sources and investigate their properties using low frequency radio observations. This thesis consists in the study of a sample of 12 cool-core galaxy clusters which present some level of dynamical disturbances on large-scale. The heterogeneity of sources in the sample allowed me to investigate under which conditions a halo-type emission is present in MH clusters; and also to study the connection between AGN bubbles and the local environment. Using high sensitivity LOFAR observations, I have detected large-scale emission in four non-merging clusters, in addition to the central MH. I have constrained for the first time the spectral properties of diffuse emission in these double radio component galaxy clusters, and I have investigated the connection between their thermal and non-thermal emission for a better comprehension of the acceleration mechanism. Furthermore, I derived upper limits to the halo power for the other clusters in the sample, which could present large-scale diffuse emission under the detection threshold. Finally, I have reconstructed the duty-cycle of one of the most powerful AGN known, located at the centre of a galaxy cluster of the sample.

Relevância:

30.00% 30.00%

Publicador:

Resumo:

Leishmaniasis is one of the major parasitic diseases among neglected tropical diseases with a high rate of morbidity and mortality. Human migration and climate change have spread the disease from limited endemic areas all over the world, also reaching regions in Southern Europe, and causing significant health and economic burden. The currently available treatments are far from ideal due to host toxicity, elevated cost, and increasing rates of drug resistance. Safer and more effective drugs are thus urgently required. Nevertheless, the identification of new chemical entities for leishmaniasis has proven to be incredibly hard and exacerbated by the scarcity of well-validated targets. Trypanothione reductase (TR) represents one robustly validated target in Leishmania that fulfils most of the requirements for a good drug target. However, due to the large and featureless active site, TR is considered extremely challenging and almost undruggable by small molecules. This scenario advocates the development of new chemical entities by unlocking new modalities for leishmaniasis drug discovery. The classical toolbox for drug discovery has enormously expanded in the last decade, and medicinal chemists can now strategize across a variety of new chemical modalities and a vast chemical space, to efficiently modulate challenging targets and provide effective treatments. Beyond others, Targeted p Protein Degradation (TPD) is an emerging strategy that uses small molecules to hijack endogenous proteolysis systems to degrade disease-relevant proteins and thus reduce their abundance in the cell. Based on these considerations, this thesis aimed to develop new strategies for leishmaniasis drug discovery while embracing novel chemical modalities and navigating the chemical space by chasing unprecedented chemotypes. This has been achieved by four complementary projects. We believe that these next-generation chemical modalities for leishmaniasis will play an important role in what was previously thought to be a drug discovery landscape dominated by small molecules.